Background. Because coronary thrombosis is important in the pathogenesis of unstable angina and correlates with in-hospital cardiac events, we hypothesized that thrombolytic therapy would decrease cardiac events.
cularization.1-3 Coronary thrombus plays a pivotal role in the pathophysiological mechanisms of unstable angina. Patients with unstable angina have an increase in platelet activity,4 and autopsy studies5 invariably show thrombus at the site of a disrupted atherosclerotic plaque. Coronary angioscopy at surgery6 has demonstrated coronary thrombus in all patients with unstable angina. Angiographic detection of coronary See p 376 thrombus has proved more variable and is importantly influenced by the time interval between symptoms and angiography.7 Moreover, we have described a link between in-hospital cardiac events such as death and myocardial infarction in unstable angina and the presence of coronary thrombus. 3, 7 Treatment with aspirin and heparin has had a favorable impact on morbidity and mortality following unstable angina. 12, 8 Given the favorable effects produced by thrombolytic therapy in acute myocardial infarction,9 it seems reasonable to assume that the resolution of coronary thrombus by thrombolytic therapy in unstable angina might result in an even more substantial reduction of cardiac events. Although previous studies using streptokinase,10 tissue plasminogen activator (t-PA),11-3 and urokinase14 in highly selected and small patient populations with unstable angina have shown successful resolution of coronary thrombi, the clinical efficacy of thrombolytic therapy in unstable angina remains controversial and unproven.
We report a double-blind, randomized, placebocontrolled study of t-PA versus placebo in unstable angina, with the principal end point being in-hospital cardiac events. Secondary end points in this trial were 1) frequency of ST shift15,16; 2) size of resting thallium defect17; and 3) frequency of coronary thrombi, minimal cross-sectional area, and stenosis morphology of the culprit coronary artery.
Methods Patient Population
From June 1988 through March 1990, all patients admitted to a single coronary care unit were considered for entry into the study. From January to March 1990, an additional 7% of the study population was enrolled from a second coronary care unit (Sunnybrook Medical Centre). Patients were eligible if they were less than 75 years of age and had ischemic chest pain at rest less than 12 hours before admission with either rapid acceleration of a previously established anginal syndrome or prolonged ischemic chest pain of more than 20 minutes' duration without persistent ST elevation. The presence of ST shift was not required for admission to the study. Patients were excluded if they had previous coronary bypass surgery, left bundle branch block, percutaneous transluminal coronary angioplasty (PTCA) or myocardial infarction within 1 month, a significant nonischemic cardiac abnormality, a serious advanced medical illness, or a contraindication to thrombolytic therapy such as recent surgery, trauma, or cerebral event.
Treatment Protocol
Patients were randomized to placebo or doublechain recombinant t-PA (Wellcome Foundation Ltd.) administered at a dose of 0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours.
All t-PA used in this study was from a single batch with a specific activity of 0.278 MU/mg. This t-PA differs from the marketed form of TPA (alteplase) in that it exists in a double-rather than a predominantly single-chain form. The recommended administration of Wellcome t-PA in acute infarction of 0.4 MU/kg in the first hour followed by 0.2 MU/kg over 2 hours results in a 90-minute coronary patency rate of 68%,18 and a similar dose significantly improves ventricular function.9 Simultaneously with start of thrombolytic therapy or placebo, all patients received intravenous heparin commencing with a bolus of 4,000 units followed by an infusion at 1,000 units per hour to maintain the partial thromboplastin time at 2 to 2.5 times normal. Intravenous heparin was continued for at least 96 hours, and 325 mg of aspirin was administered daily beginning on the third day in hospital and for the remainder of the patient's hospitalization. Medical therapy was standardized and consisted of topical nitrates in all patients with addition of calcium antagonists, 8l-blockers, or both at the discretion of the attending cardiologist according to recurrence of chest pain.
Serial creatine kinase and MB fraction were assessed every 8 hours for 48 hours. Myocardial infarction on admission was defined as a creatine kinase rise of more than 2 times normal in the first 12 hours of admission without intervening recurrence of chest pain and with an elevated creatine kinase-MB fraction.
Holter Monitoring
A Holter monitor (Marquette #7010 AM system) was used for assessment of frequency and duration15 of ST segment shift in two leads (V5, aVF) during the first 48 hours after start of therapy. An episode of significant ST shift was defined as ST elevation or horizontal or downsloping ST depression of 0.1 mV or more 0.08 seconds from the J point, lasting 1 minute or longer and separated from other episodes by 1 minute or longer. All episodes were confirmed by one observer blinded to the clinical course and treatment allocation.
Thallium Scintigraphy
At 90 minutes after initiation of the study drug, 2.2 mCi of thallium was administered intravenously; planar imaging in three standard views was begun 20 minutes after the injection. Thallium scintigrams were quantitatively analyzed for defect size (in degrees of circumferential profile) by comparison with normal limits by a previously reported method.17 To account for previous myocardial infarction, we subtracted the defect in the territory of previous Q wave myocardial infarction from the total defect size.
Coronary Angiography
At 18+6 hours after initiation of the study drug, coronary angiography was undertaken with angiograms of the culprit lesion obtained in orthogonal projections. One of the investigators (R.W.), blinded to all aspects of the study, determined the unstable angina-provoking vessel in each patient, defined as the vessel with the most complicated and severe lesion. After magnification of the lesion, the presence of intracoronary thrombus defined as 1) an intraluminal filling defect outlined by contrast on three sides; 2) a discrete portion of an artery with a hazy, irregular border associated with a decrease in contrast density persisting throughout the cardiac cycle; or 3) the presence of an ulcerated area with associated filling defects within or around the edge of the ulcer was established.
Quantitative coronary angiography was performed on each visually assessed stenosis of 50% or greater (Reiber-PIE method).19 The percent diameter and area of stenosis, minimal-lesion crosssectional area,19 and ulceration index20 were assessed in lesions where good recognition of the coronary lumen was possible in the unstable angina-provoking vessel. The ulceration index is an objective assessment of lesion complexity and is calculated as the ratio of the absolute diameter of least severe stenosis within the lesion to the maximal intralesional diameter. A value less than 0.83 is observed more frequently in unstable angina than in stable angina.20 A left ventricular jeopardy score was calculated for each patient according to a modification of the method of Califf et al.21
Exercise Thallium Scintigraphy
Once resting pain had resolved for at least 24 hours, the patients underwent exercise thallium scintigraphy using a standard Bruce protocol exercise test. Medications were withheld the morning of the exercise test when possible. Quantitative thallium tomography was performed according to a previously described method. 22 We determined exercise duration, presence and severity of ST segment shift defined as 0.1 mV or more horizontal or downsloping ST depression at 0.08 seconds after the J point, maximum heart rate and systolic blood pressure, and size (in percentage of total myocardium) of reversible and nonreversible thallium defect. 9, 22 Tnial End Points
The principal end points of this trial were inhospital cardiac events consisting of cardiac death, myocardial infarction defined as a significant rise in creatine kinase from baseline with an elevated MB fraction not associated with presenting chest pain,23 and urgent revascularization with either PTCA or coronary artery bypass graft surgery. Revascularization performed for persistent chest pain at rest despite maximal medical therapy that included intravenous nitroglycerin was considered urgent. We also recorded the performance of elective PTCA or coronary artery bypass graft surgery, but this was not considered an end point.
We evaluated secondary end points that have prognostic significance in unstable angina. These end points included 1) frequency and duration of ST shift15,16; 2) presence and size of resting thallium defect'7; and 3) frequency of coronary thrombi, minimal cross-sectional area, and stenosis morphology of the culprit coronary artery.
Severe adverse noncardiac events including central nervous system hemorrhage, bleeding, and transfusion requirements were carefully monitored. The study protocol was approved by the Ethics Committee of the University of Toronto. Results During the study period, 652 patients admitted with unstable angina were screened for enrollment. The reasons for nonenrollment were absence of admission criteria (18%) or the presence of exclusion criteria: 1) recent infarction or PTCA (18%); 2) previous aortocoronary bypass surgery (12%); 3) age greater than 75 years (10%); 4) contraindications to thrombolytic therapy (9%); 5) miscellaneous (6%); or 6) patient refusal (16%). The remaining 70 patients were enrolled in the study, with 35 randomized to t-PA and 35 to placebo. The two patient groups had comparable clinical characteristics, medical therapy on admission, and aspirin administration in the 24 hours before admission (Table 1 ). Four patients in each treatment group subsequently were shown to have had myocardial infarction on admission, and their maximum creatine kinase levels were similar (541+274 in the t-PA group versus 521±238 in the placebo group). The patients enrolled from the two coronary care units were similar.
Cardiac Events
The primary end points of our study, clinical outcomes during hospitalization, are shown in Table  2 . Three patients, two in the t-PA group and one in the placebo group, had a significant rise in total creatine kinase after admission. One patient receiving t-PA and four receiving placebo required urgent angioplasty (p =0.18). One patient in each group required urgent coronary bypass graft surgery, and one patient in each group died. Hence, there was no difference in total cardiac events between patients receiving t-PA (five patients, 14%) compared with those receiving placebo (seven patients, 20%), p=0.83. Six patients in each group underwent elective revascularization. There was no difference in cardiac event rates in the patients with or without ST shift on the admission ECG.
Secondary End Points
The angiographic findings were acquired at 18±3 hours for the t-PA group and 19+4 hours for the placebo group. The extent of angiographic coronary artery disease (stenoses 50% or greater) was similar in the two treatment groups. Of the 31 patients randomized to t-PA who had angiography, nine had no stenosis 50% or greater, 12 had one-vessel disease, six had two-vessel disease, and four had threevessel disease. Similarly, of the 35 patients randomized to placebo, nine had no stenosis 50% or greater, 14 had one-vessel disease, four had two-vessel disease, and eight had three-vessel disease. Of the 18 patients with no stenosis 50% or greater, seven had stenoses less than 50% and 11 had entirely normal coronary arteries. The anatomic location of the culprit vessel and the jeopardy score were similar in the two treatment groups ( Table 3 ). Subsequent analyses of coronary thrombus, stenosis severity, and ulceration index, excluding the nine patients in each group who had no stenosis 50% or greater, are shown in Figures 1 and 2 . There was a highly significant reduction in coronary thrombus with the administration of t-PA as compared with placebo ( Figure 1 ), but Defect size in degrees of circumferential profile. MI, myocardial infarction; UA territory, defect size in territory of unstable angina-provoking stenosis. phy, and the inclusion of these patients in the comparison of coronary thrombus did not affect the statistical significance between the two groups. In addition, the lack of statistical differences in minimal cross-sectional area and ulceration index between t-PA and placebo persisted despite inclusion of the quantitative analysis of coronary lesions in the seven patients with stenoses less than 50%.
A comparison of Holter assessment of ST segment shift and resting thallium defect size is shown in Table 4 . More frequent episodes of ST shift and a greater duration of ST shift occurred in the patients receiving t-PA than in those receiving placebo. In the t-PA group, two of nine episodes of ST shift were elevation, whereas in the placebo group, three of four were ST elevation, p =0.11. Thallium defect size was significantly greater in t-PA patients than in placebo patients. Thallium defect size in the territory of the unstable angina-provoking vessel was greater in the t-PA patients than in the placebo patients. After correction for defects in the area of previous infarction, thallium defect size remained significantly larger in the t-PA patients than in the placebo patients.
The exercise thallium scintigraphic data in 20 t-PA patients and 24 placebo patients are shown in Table  5 . There was no significant difference between the t-PA patients and the placebo patients with respect to all exercise variables and reversible and total defect size by tomographic thallium scintigraphy. The only significant difference was in maximum heart rate, which was higher in the patients receiving t-PA. Safety There were two cerebral vascular accidents during the study. One patient receiving t-PA had an intracerebral bleed in the first 24 hours with complete recovery, and one patient receiving placebo had a nonhemorrhagic cerebral vascular accident at 72 hours. No significant noncerebral bleeding complications were identified, and no patient required a transfusion.
Discussion
In this study, we found no difference in clinical outcome in unstable angina with t-PA therapy despite an impressive reduction of intracoronary thrombus. It is noteworthy that treatment in the placebo group with heparin alone resulted in a low frequency *Concluded heparin superior to t-PA in preventing recurrent pain and cardiac events; data not clearly given in report. §Minimal cross-sectional area. NS, no difference of paired comparisons.
of in-hospital cardiac events. The failure to improve clinical outcome with t-PA therapy was further substantiated by the lack of change in coronary stenosis complexity or severity. Paradoxically, our data suggest that t-PA therapy in unstable angina may be detrimental, as suggested by an increase in ST shift on Holter monitoring and an increase in resting thallium defect size. Three previous uncontrolled studies of thrombolytic therapy in unstable angina demonstrated potential benefits.10,"''4 A summary of five randomized placebo-controlled studies including the present study of t-PA in unstable angina is shown in Table 6 . Only the study of Gold et al12 suggested clinical benefits, and it is interesting to note that there was a 55% event rate in the placebo group.
We failed to show any treatment effect on coronary stenosis severity or complexity using quantitative coronary angiography. These findings are similar to those of Williams et al,25 who showed no difference in diameter or area of stenosis with either low or high doses of t-PA compared with heparin in unstable angina. They did show a small but significant improvement in culprit artery stenosis severity with low doses of t-PA compared with angiograms performed before initiation of therapy, but paradoxically, there was no difference in angiographic thrombus between patients treated with t-PA and those treated with heparin therapy. The disparity between these findings and our own is probably related to the difference in timing of therapy with respect to resting pain onset; Williams et al initiated therapy up to 7 days following resting pain, whereas we initiated therapy within 12 hours of resting pain. The low frequency of thrombus in the study of Williams et al probably represents spontaneous resolution of thrombus before initiation of therapy, because we have previously shown that the frequency of coronary thrombus identified at angiography is related to timing of the procedure and resting pain.7
The frequency of coronary thrombi in our placebo patients with a significant stenosis is higher than we have previously reported7 and is probably part a result of lesion magnification in this study and the performance of angiography within 12 hours as opposed to 24 hours of resting pain. Moreover, our frequency of intracoronary thrombi is similar to that reported in the placebo group by Gold et al,12 90% in patients with a significant stenosis, and Forrester et al,27 87% by coronary angioscopy. As the ulceration index was unchanged with t-PA therapy, it appears that t-PA dissolves intraluminal clot but does not completely resorb thrombus contained in the ruptured atherosclerotic plaque. The lack of total resolution of intracoronary thrombi is consistent with a study of intracoronary streptokinase in acute infarction that demonstrated incomplete lysis of intracoronary thrombus in most patients. 28 It is important to consider the effect of heparin on our outcome measures in the placebo group. In our previous studies of patients with unstable angina with similar admission criteria who did not receive heparin, the frequency of cardiac events was 39% (52 of 135 patients).'5 Although caution must be exercised in such comparisons, it is noteworthy that we found a significantly lower overall cardiac event rate in the current study (12 of 70 patients, 17%, p =0.002) and that this event frequency is similar to that documented for heparin in unstable angina by Theroux et al. 8 Further support of a heparin treatment effect is provided by the reduced frequency of ST shift by Holter monitoring in this study compared with our previous report (2+10 minutes versus 78±120 minutes)15 and that of Gottlieb et al,'6 where intravenous heparin was not used routinely.
Some comment about the timing of aspirin administration in our study seems warranted. We did not initiate aspirin therapy until 72 hours after admission. The clinical efficacy of earlier use of aspirin in addition to heparin has not been established: Ther-oux et a18 showed no increased benefit of aspirin in addition to heparin in unstable angina but did show an increase in bleeding complications. Serneri et a126 also showed no benefit of aspirin for silent ischemia or events in unstable angina. Combined t-PA and aspirin administration without heparin early in myocardial infarction leads to reduced thrombolytic efficacy compared with t-PA with heparin.29 The clinical effect of earlier administration of aspirin with t-PA therapy in unstable angina is unknown and may require further investigation.
Although there was no difference in the number of patients with ST shift, there was an increase in frequency and duration of ST shift by Holter monitoring in patients receiving t-PA compared with those receiving placebo. It is interesting to compare our observations with those of Serneri et al,26 who recently reported on the effects of heparin, aspirin, and t-PA on myocardial ischemia in unstable angina. In 40 patients in whom medical therapy failed, these authors noted that heparin was more effective than t-PA administered without heparin in reducing silent ischemic episodes. We also found that thallium defects were more frequent and larger in the patients receiving t-PA than in those receiving placebo, despite the fact that thallium injection occurred 90 minutes after start of therapy at a time of probable maximal thrombolytic efficacy of the t-PA. Because resting thallium defects may also be found in territories supplied by nonculprit vessels in patients with multivessel disease,17 we corroborated the association between t-PA therapy and more frequent and larger thallium defects by examining only those thallium defects in the territories supplied by the unstable angina-provoking vessel. When this was done, the differences between t-PA and placebo persisted and also remained after correction for previous myocardial infarction (Table 4 ). Our study of t-PA combined with heparin provides the first evidence that points toward possible aggravation of ischemia with this therapy.
The reasons for more frequent ST shift and larger thallium defects with t-PA are unclear but may be related to 1) an augmented potential for thrombus formation mediated by an increase in platelet aggregation after thrombolytic therapy,30 2) reduction of free plasminogen by continued infusion of t-PA with resultant depletion of clot-associated plasminogen,31 and 3) distal embolization of intracoronary thrombi. The propensity for recurrent ischemia after thrombolytic therapy for acute myocardial infarction is well established and agrees with our findings in unstable angina. 32 Once the patients had stabilized, we assessed exercise performance with Bruce protocol stress ECG and tomographic thallium scintigraphy. There were no differences between the t-PA and placebo patients.
Limitations of Study
It is appropriate to evaluate the power of our study. If the cardiac event rate as shown in our study was a true reflection of t-PA treatment, a total of 611 patients per group would be required to demonstrate statistical significance with a power of 80%. If such a difference exists, the ongoing larger TIMI 3 study, which began after our own study, should have the necessary sample size to demonstrate a difference in cardiac event rates in unstable angina patients receiving thrombolytic therapy compared with those receiving heparin alone. We used only one type and mode of administration of thrombolytic therapy; alternative therapy with different regimens and earlier aspirin administration might have resulted in a different outcome.
The identification of the unstable angina-related lesion by angiographic criteria may conceivably lead to misclassification. Wilson et a120 previously demonstrated that an ulceration index of less than 0.83 is sensitive and specific for unstable angina in patients with single-vessel disease. In our population, only 33% of the patients had multivessel disease, and in these patients, the ulceration index was more than 0.83 in 95% of the non-unstable angina-designated lesions and less than 0.83 in 70%o of the unstable angina-designated lesions. Hence, misclassification of the unstable angina-provoking stenosis seems unlikely.
Given the modest sample size in this study, the comparability of the two treatment groups may be in question. There were no differences in commonly evaluated clinical variables, admission ECG, coronary anatomy, location of culprit vessel, and coronary jeopardy score. The design of our study mandated early administration of therapy and therefore precluded baseline evaluation of thallium perfusion and Holter ST data. The deleterious effects of t-PA demonstrated in this study are predicated upon the assumption that the similarity of the two treatment groups extended to thallium and Holter ST variables; this requires confirmation from other investigations.
Conclusions
We conclude that a prolonged infusion of t-PA in unstable angina reduces intracoronary thrombi. Although there was no concomitant decrease in in-hospital cardiac events, our sample size does not provide adequate power to rule out a treatment effect. Paradoxically, there appears to be an increase in ST shift and worsening of myocardial perfusion with t-PA compared with therapy with heparin alone. The significance of these findings and the potential role of other thrombolytic strategies warrant further investigation.
